ANGPTL1 and metabolic syndrome: A recently completed phase 2b, multicenter, double-blinded, placebo-controlled, parallel-group study, the PROLONG-ANG3 study, administered three different dosage regimens of solbinsiran or a placebo to 175 patients with mixed dyslipidemia to assess the efficacy and safety of the agent.